Literature DB >> 31718909

Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma.

Jae-Won Hyun1, Geun Soo Kim2, Su-Hyun Kim1, Joong-Yang Cho2, Ho Jin Kim1, Geon Kook Lee3, Hak Jin Kim4, Sung Uk Kwon5.   

Abstract

Entities:  

Keywords:  Immune-related adverse events; Myasthenia gravis; Myocarditis; PD-1; Thymoma

Mesh：

Substances：

Year:  2019        PMID： 31718909     DOI： 10.1016/j.cllc.2019.10.008

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN： 1525-7304            Impact factor:   4.785


× No keyword cloud information.
  3 in total

1.  Intrinsic Differences in Immune Checkpoint Inhibitor-Induced Myocarditis: A Retrospective Analysis of Real World Data.

Authors:  Yanna Lei; Xiufeng Zheng; Qian Huang; Xiaoying Li; Meng Qiu; Ming Liu
Journal:  Front Pharmacol       Date:  2022-07-05       Impact factor: 5.988

2.  Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung.

Authors:  Xiaohong Xie; Fei Wang; Yinyin Qin; Xinqing Lin; Zhanhong Xie; Ming Liu; Ming Ouyang; Bihui Luo; Yingying Gu; Shiyue Li; Dejian Gu; Rongrong Chen; Chengzhi Zhou
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

3.  Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.

Authors:  Li Shen; Haiyan Chen; Qichun Wei
Journal:  Front Immunol       Date:  2021-04-15       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.